文献速递复苏、休克与脓毒症心脑血管急症

评估体外膜氧合对院外心脏骤停疗效的自适应临床试验设计

The Design of an Adaptive Clinical Trial to Evaluate the Efficacy of Extra-Corporeal Membrane Oxygenation for Out-of-Hospital Cardiac Arrest.
PubMed 文献 · Resuscitation · 2020-11-19
一句话结论提出一项贝叶斯自适应富集试验设计,用于确定ECPR对难治性院外心脏骤停是否有效及获益的骤停至ECPR时间窗。

该文报告了一项针对成人非创伤性院外心脏骤停的ECPR随机贝叶斯自适应试验设计。受试者1:1随机接受标准治疗或加速转运至医院接受潜在ECPR。主要终点为90天效用加权改良Rankin量表(uwmRS),按初始心律(可除颤 vs 不可除颤)分层。最大样本量400例(不可除颤亚组上限300例),设计对不可除颤心律把握度91-100%,可除颤心律69-98%,并可识别ECPR产生临床显著获益(uwmRS差异0.2)的最大骤停至ECPR时间窗。

要点

  • 试验纳入成人非创伤性院外心脏骤停患者,随机1:1接受标准治疗或加速转运至医院接受潜在ECPR。
  • 主要终点为90天效用加权改良Rankin量表(uwmRS),按初始心律(可除颤 vs 不可除颤)分层分析。
  • 骤停至ECPR时间窗通过实时估计的急救反应时间、现场时间和转运时间之和确定,并采用贝叶斯递减阶梯函数自适应调整。
  • 最大样本量400例,不可除颤心律亚组上限300例;设计把握度不可除颤91-100%,可除颤69-98%。
  • 若ECPR无效,不可除颤亚组99%概率、可除颤亚组97%概率因无效提前终止;I类错误率2.5%。

适用人群与场景

  • 成人非创伤性院外心脏骤停患者,标准治疗难治。
  • 按初始心律分为可除颤和不可除颤两个亚组。
  • 排除创伤性院外心脏骤停。

诊断标准与关键阈值

  • 骤停至ECPR时间窗通过实时估计的急救反应时间(911呼叫至到达现场)、现场时间和转运至医院时间之和确定。
  • 采用贝叶斯递减阶梯函数估计ECPR疗效,主要结局为90天uwmRS。
  • 若治疗在初始资格窗上限显示有效,则自适应延长估计的骤停至ECPR资格窗;若在较长间隔显示无效,则缩短入组资格窗上限。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究设计为随机贝叶斯自适应富集临床试验,计划最大样本量400例,不可除颤心律亚组最大样本量300例。
  • 干预为加速转运至医院接受潜在ECPR,对照为标准治疗,随机比例1:1。
  • 主要终点为90天uwmRS,按心律亚组分层分析。
  • 设计把握度:不可除颤心律91-100%,可除颤心律69-98%(各种模拟疗效场景下)。
  • 正确识别ECPR产生临床显著获益(uwmRS差异0.2)的最大骤停至ECPR时间窗的概率高。
  • 若ECPR等效于标准治疗,I类错误率2.5%,不可除颤亚组99%概率、可除颤亚组97%概率因无效提前终止入组。

证据类型、等级与局限

  • 证据类型:临床试验设计报告(贝叶斯自适应随机试验设计),非结果性RCT。
  • 局限:为模拟设计特征,非实际试验结果;尚未有多中心随机临床试验确立ECPR疗效。

对床旁实践的改变

  • 该设计支持根据心律亚组和估计的骤停至ECPR时间窗富集最可能获益的患者入组。
  • 若试验实施,可能改变院外心脏骤停患者转运决策和ECPR资格窗的确定方式。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal cardiopulmonary resuscitation (ECPR) is a promising therapy for out-of-hospital cardiac arrest (OHCA) that is refractory to standard therapy, but no multicenter randomized clinical trials have been conducted to establish its efficacy. We report the design and operating characteristics of a proposed randomized Bayesian adaptive "enrichment" clinical trial designed to determine whether ECPR is effective for refractory OHCA and, if effective, to define the interval after arrest during which patients derive benefit.

METHODS: Through iterative trial simulation and trial design modification, we developed a Bayesian adaptive trial of ECPR for adults who experience non-traumatic out-of-hospital cardiac arrest. Our proposed trial design addresses the threats to trial success identified during the design process, which were (1) the uncertainty surrounding the cardiac arrest (CA)-to-ECPR interval within which clinical benefit might be preserved (2) the difference in prognosis between patients with an initial rhythm that is non-shockable vs. shockable. Trial subjects will be randomized 1:1 to receive either standard care or expedited transport to a hospital for potential ECPR. The CA-to-ECPR interval will be estimated in real time based on the sum of the estimated paramedic response time (911 call to scene arrival), paramedic scene time, and transport time to hospital. A Bayesian decreasing step function will be used to estimate the efficacy of the treatment with an outcome of the 90-day utility-weighted Modified Rankin Scale (uwmRS) for each rhythm subgroup and estimated CA-to-ECPR interval at pre-specified interims. The trial will adaptively lengthen the estimated CA-to-ECPR eligibility window if the treatment appears effective at the upper limit of initial eligibility window. If ECPR appears ineffective at longer estimated CA-to-ECPR intervals, the upper limit of the window for enrollment eligibility will be shortened. The analysis will be stratified by rhythm subgroup.

RESULTS: With a maximum total sample size of 400, and a cap on the maximum sample size of 300 for the non-shockable rhythm subgroup, the trial design has power ranging from 91-100% to detect a benefit from ECPR for non-shockable rhythms under the various efficacy scenarios simulated and power ranging from 69-98% for shockable rhythms under the same scenarios. The trial design also has a high probability of correctly identifying the maximum CA-to-ECPR interval within which ECPR produces a clinically significant benefit of 0.2 on the uwMRS. If ECPR is equivalent to standard CA care, the type I error is 2.5% with a 99% probability of stopping enrollment early for futility in the non-shockable subgroup and a 97% probability of stopping enrollment early for futility in the shockable subgroup.

CONCLUSION: This proposed adaptive trial design helps to ensure the population of patients who are most likely to benefit from treatment-as defined both by rhythm subgroup and estimated CA-to-ECPR interval-is enrolled. The design promotes early termination of the trial if continuation is likely to be futile.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Tolles J, Kidwell KM, Broglio K, et al. The Design of an Adaptive Clinical Trial to Evaluate the Efficacy of Extra-Corporeal Membrane Oxygenation for Out-of-Hospital Cardiac Arrest. Resuscitation. 2020. PMID: 33221363. doi:10.1016/j.resuscitation.2020.11.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。